The tumor-suppressive outcome is driven by combined molecular changes: downregulation of SPARCL1 and PSME3, coupled with upregulation of the NF-κB inhibitor NFKBIA and downregulation of CD44 and CCL15, collectively promotes apoptosis while suppressing proliferation, migration, and angiogenesis. The gene discussed is NFKBIA; the disease is neoplasm.